ATE481979T1 - Kombination aus einem anti-edb-fibronectin- domänen-antikörper/il2-fusionsprotein und einem weiteren kleinen molekül - Google Patents

Kombination aus einem anti-edb-fibronectin- domänen-antikörper/il2-fusionsprotein und einem weiteren kleinen molekül

Info

Publication number
ATE481979T1
ATE481979T1 AT07724281T AT07724281T ATE481979T1 AT E481979 T1 ATE481979 T1 AT E481979T1 AT 07724281 T AT07724281 T AT 07724281T AT 07724281 T AT07724281 T AT 07724281T AT E481979 T1 ATE481979 T1 AT E481979T1
Authority
AT
Austria
Prior art keywords
fusion protein
combination
small molecule
domain antibodies
another small
Prior art date
Application number
AT07724281T
Other languages
English (en)
Inventor
Andreas Menrad
Hans Dietrich Menssen
Karola Wagner
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa filed Critical Philogen Spa
Application granted granted Critical
Publication of ATE481979T1 publication Critical patent/ATE481979T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT07724281T 2006-04-07 2007-04-05 Kombination aus einem anti-edb-fibronectin- domänen-antikörper/il2-fusionsprotein und einem weiteren kleinen molekül ATE481979T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06090054A EP1842553A1 (de) 2006-04-07 2006-04-07 Kombination von einem Anti-EDb Fibronektin Domäne Antikörper/ IL2 Fusionsprotein und einem kleinen Molekül
US79686606P 2006-05-03 2006-05-03
PCT/EP2007/003343 WO2007115837A2 (en) 2006-04-07 2007-04-05 Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule

Publications (1)

Publication Number Publication Date
ATE481979T1 true ATE481979T1 (de) 2010-10-15

Family

ID=36811417

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07724281T ATE481979T1 (de) 2006-04-07 2007-04-05 Kombination aus einem anti-edb-fibronectin- domänen-antikörper/il2-fusionsprotein und einem weiteren kleinen molekül

Country Status (8)

Country Link
US (1) US7851599B2 (de)
EP (2) EP1842553A1 (de)
JP (1) JP5096456B2 (de)
AT (1) ATE481979T1 (de)
CA (1) CA2648109C (de)
DE (1) DE602007009373D1 (de)
ES (1) ES2352161T3 (de)
WO (1) WO2007115837A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
US20090110680A1 (en) * 2006-04-07 2009-04-30 Stephanie Sieger Combination of an anti ED-B fibronectin domain antibody and gemcitabine
EP1925664A1 (de) 2006-11-15 2008-05-28 Scil proteins GmbH Künstliche Bindungsproteine auf Grundlage einer modifizierten alpha-Helix Region von Ubiquitin
ES2382058T3 (es) 2008-01-17 2012-06-04 Philogen S.P.A. Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos
AU2010332932B2 (en) 2009-12-14 2013-01-17 Navigo Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin
JP6146821B2 (ja) 2011-06-15 2017-06-14 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングNavigo Proteins GmbH 修飾ユビキチンに基づく二量体型結合タンパク質
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
CN104470535A (zh) * 2012-03-29 2015-03-25 阿尔托生物科学有限公司 用于治疗肿瘤的方法
US10611830B2 (en) * 2013-06-06 2020-04-07 Hefei Lifeon Pharmaceutical Co. Ltd. Human antibody against ED-B domain of fibronectin and uses thereof
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングNavigo Proteins GmbH 新規なegfr結合タンパク質
AU2016293063B2 (en) 2015-07-16 2018-11-08 Navigo Proteins Gmbh Novel immunoglobulin-binding proteins and their use in affinity purification
JP2018520675A (ja) 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングNavigo Proteins GmbH ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
EP3452097A1 (de) 2016-05-04 2019-03-13 Navigo Proteins GmbH Zielgerichtete verbindungen zur stellenspezifischen kupplung chemischer einheiten mit einem peptidlinker
SG11201901066UA (en) 2016-08-11 2019-03-28 Navigo Proteins Gmbh Novel alkaline stable immunoglobulin-binding proteins
SG11201903400WA (en) * 2016-10-17 2019-05-30 Pfizer Anti-edb antibodies and antibody-drug conjugates
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
US11883503B2 (en) * 2017-09-25 2024-01-30 Dingfu Biotarget Co., Ltd. Methods and compositions for cancer treatment
WO2019091918A1 (en) 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
EP3660039A1 (de) 2018-11-30 2020-06-03 Philogen S.p.A. Il2-immunkonjugate
MA54501A (fr) 2018-12-18 2021-10-27 Navigo Proteins Gmbh Nouvelles protéines de liaison spécifiques de folr1 pour le diagnostic et le traitement du cancer
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
CN119072328A (zh) 2022-03-23 2024-12-03 菲洛根股份公司 Il2免疫缀合物制剂
CN119836298A (zh) 2022-09-01 2025-04-15 菲洛根股份公司 用于非黑色素瘤皮肤癌的TNFα和白细胞介素-2组合疗法
WO2025061801A1 (en) 2023-09-19 2025-03-27 Philochem Ag Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
WO2026003203A1 (en) 2024-06-27 2026-01-02 Philogen S.P.A. Combination of an immunocytokine comprising targeted il2 and a jak inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
ATE333900T1 (de) * 2000-02-24 2006-08-15 Philogen Spa Zusamensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen

Also Published As

Publication number Publication date
CA2648109A1 (en) 2007-10-18
US7851599B2 (en) 2010-12-14
JP5096456B2 (ja) 2012-12-12
DE602007009373D1 (de) 2010-11-04
WO2007115837A3 (en) 2008-01-24
WO2007115837B1 (en) 2008-03-27
US20090110660A1 (en) 2009-04-30
EP2007415A2 (de) 2008-12-31
EP2007415B1 (de) 2010-09-22
JP2009532408A (ja) 2009-09-10
CA2648109C (en) 2012-09-25
ES2352161T3 (es) 2011-02-16
EP1842553A1 (de) 2007-10-10
WO2007115837A2 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
ATE481979T1 (de) Kombination aus einem anti-edb-fibronectin- domänen-antikörper/il2-fusionsprotein und einem weiteren kleinen molekül
PT2061814E (pt) Anticorpos e imunoconjugados e suas utilizações
CR10273A (es) "anticuerpos anti-5t4 y usos de los mismos"
CY1114926T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
NO2017032I1 (no) bezlotoksumab
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
DK1963368T3 (da) Anti-il-17-antistoffer
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
HUE048404T2 (hu) Claudin-18 elleni monoklonális antitestek rák kezelésére
CU20120095A7 (es) Antagonistas de pcsk9
ATE544862T1 (de) Promotorsequenz aus reis, und verfahren für ihre verwendung
ATE541857T1 (de) Optimierte fc-varianten und herstellungsverfahren dafür
MEP35408A (en) Tweak binding antibodies
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
CY1114658T1 (el) Πρωτεϊνες δεσμευσης αντιγονου του αυξητικου παραγοντα τυπου επιδερμικου αυξητικου παραγοντα προσδεσης στην ηπαρινη
CY1113224T1 (el) Νεο αντισωμα αντι-ρlgf
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
NI201100107A (es) Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente la cd38 y la citarabina.
DE602006021441D1 (de) Schlauch zur beförderung von kryogenen fluiden
DK1948692T3 (da) Kimære RANKL antistof-PTH/PTHrP-molekyler
IL213523A0 (en) Compositions comprising blood group antigens
ATE496943T1 (de) Biotinylierte mhc-komplexe und ihre verwendungen
DE602008001068D1 (de) Entschwefelungsverfahren von Kohlenwasserstofffraktionen, die aus dampfgekrackten Abgasen stammen
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
BRPI0715544A2 (pt) Anticorpos que modificam doença cancerosas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2007415

Country of ref document: EP